Histological spatial analysis on the induction of PD-L1+ macrophages by CD8+ T cells at the marginal microenvironment of triple-negative breast cancer
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Histological spatial analysis on the induction of PD-L1+ macrophages by CD8+ T cells at the marginal microenvironment of triple-negative breast cancer
Authors
Keywords
-
Journal
Breast Cancer
Volume 30, Issue 6, Pages 1094-1104
Publisher
Springer Science and Business Media LLC
Online
2023-10-04
DOI
10.1007/s12282-023-01507-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Regulation of PD-L1 expression in the tumor microenvironment
- (2021) Ming Yi et al. Journal of Hematology & Oncology
- Tumor‐associated macrophage‐derived transforming growth factor‐β promotes colorectal cancer progression through HIF1‐TRIB3 signaling
- (2021) Changfu Liu et al. CANCER SCIENCE
- Role of the CCL2‐CCR2 signalling axis in cancer: Mechanisms and therapeutic targeting
- (2021) Maosen Xu et al. CELL PROLIFERATION
- Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer
- (2021) Dora Hammerl et al. Nature Communications
- Identification of Key Genes Affecting the Tumor Microenvironment and Prognosis of Triple-Negative Breast Cancer
- (2021) Jiarong Yi et al. Frontiers in Oncology
- Breast cancer cell-derived soluble CD44 promotes tumor progression by triggering macrophage IL-1β production
- (2020) Jeong-Hoon Jang et al. CANCER RESEARCH
- Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma
- (2020) Raza Syed Hoda et al. MODERN PATHOLOGY
- Cytotoxic CD8+ T cells in cancer and cancer immunotherapy
- (2020) Hans Raskov et al. BRITISH JOURNAL OF CANCER
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
- (2020) Javier Cortes et al. LANCET
- Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
- (2019) Xianjie Jiang et al. Molecular Cancer
- Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers
- (2019) Tina Gruosso et al. JOURNAL OF CLINICAL INVESTIGATION
- A C-X-C chemokine receptor type 2-dominated crosstalk between tumor cells and macrophages drives gastric cancer metastasis
- (2019) Zhijun Zhou et al. CLINICAL CANCER RESEARCH
- Inflammatory Breast Cancer Promotes Development of M2 Tumor-associated Macrophages and Cancer Mesenchymal Cells Through a Complex Cytokine Network
- (2019) Amanda Valeta-Magara et al. CANCER RESEARCH
- The Tumor Microenvironment Innately Modulates Cancer Progression
- (2019) Dominique C. Hinshaw et al. CANCER RESEARCH
- Immune cell PD-L1 co-localizes with macrophages and is associated with outcome in PD-1 pathway blockade therapy
- (2019) Yuting Liu et al. CLINICAL CANCER RESEARCH
- Mechanisms regulating PD-L1 expression on tumor and immune cells
- (2019) Shuming Chen et al. Journal for ImmunoTherapy of Cancer
- Breast cancer cells promote CD169+ macrophage-associated immunosuppression through JAK2-mediated PD-L1 upregulation on macrophages
- (2019) Weiqiang Jing et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- The Presence of Cyclooxygenase 2, Tumor-Associated Macrophages, and Collagen Alignment as Prognostic Markers for Invasive Breast Carcinoma Patients
- (2018) Karla Esbona et al. AMERICAN JOURNAL OF PATHOLOGY
- Regulation and Function of the PD-L1 Checkpoint
- (2018) Chong Sun et al. IMMUNITY
- Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti–PD-1 treatment
- (2018) Elisa Peranzoni et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abstract A063: Cancer cell expression of CCR2 regulates the PD-L1/ PD-1 immune checkpoint in breast cancer
- (2016) Miriam R. Fein et al. Cancer Immunology Research
- Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer
- (2015) Kristin J. Lastwika et al. CANCER RESEARCH
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis
- (2013) D. E. Sanford et al. CLINICAL CANCER RESEARCH
- Innate and adaptive immune cells in the tumor microenvironment
- (2013) Thomas F Gajewski et al. NATURE IMMUNOLOGY
- Microenvironmental regulation of tumor progression and metastasis
- (2013) Daniela F Quail et al. NATURE MEDICINE
- Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
- (2013) S. Spranger et al. Science Translational Medicine
- The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients
- (2012) Catharina Medrek et al. BMC CANCER
- CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
- (2011) Bin-Zhi Qian et al. NATURE
- Triple-Negative Breast Cancer
- (2010) William D. Foulkes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1
- (2009) Dong-Ming Kuang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Cancer related inflammation: The macrophage connection
- (2008) Antonio Sica et al. CANCER LETTERS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now